Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial of Topical ASP-1001 (Contrast Media Formulation) in the Prevention of the Signs and Symptoms of the Acute Response to Nasal Allergen Challenge (NAC).
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs ASP 1001 (Primary)
- Indications Allergic rhinitis; Grass pollen hypersensitivity; Hypersensitivity
- Focus Therapeutic Use
- 01 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Jun 2010 New trial record